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Abstract
Background: Endothelial dysfunction (ED) frequently precedes cardiovascular diseases 
(CVD) and is a well-established risk factor of major adverse cardiac events. Beta-blockers are 
the fundamental drugs used in CVD treatment.
Methods: A systematic literature search for randomized controlled trials investigating influ-
ence of beta-blockers on endothelial function assessed by flow-mediated dilation (FMD) was 
performed in the PubMed and Cochrane Databases.
Results: Sixteen full-text studies involving a total of 1,273 patients were included in the final 
analysis. The mean age of participating patients ranged from 44.9 to 63.2 years, the follow-up 
duration from 1 to 12 months. The comparison of FMD change between the beta-blockers and 
placebo groups showed a statistically significant effect of beta-blockers on endothelial func-
tion (mean difference [MD] 0.83; 95% confidence interval [CI] 0.11–1.55; p = 0.02). Third 
generation beta-blockers improved FMD in a statistically significant manner compared with 
second generation beta-blockers (MD 1.65; 95% CI 0.17–3.11; p = 0.03). Beta-blockers gave 
an FMD change similar to that obtained with angiotensin receptor blockers (ARB), calcium 
channel blockers (CCB) or hydrochlorothiazide. The FMD value in the beta-blocker group was 
significantly lower compared with the group treated with angiotensin converting enzyme inhibi-
tors (ACEI) (MD –0.79; 95% CI –1.37–(–0.21); p = 0.008) and higher than in the ivabradine 
group (1.6 ± 3.61 vs –0.3 ± 1.66; p = 0.02).
Conclusions: Beta-blockers improve the endothelial function compared with placebo. More-
over, third generation beta-blockers improve FMD values significantly better than the second 
generation ones. Beta-blockers had similar effect on endothelial function as did ARB, CCB or 
diuretics. However, the beneficial effect of beta-blockers was lower when confronted with ACEI. 
(Cardiol J 2015; 22, 6: 708–716)
Key words: flow mediated dilation, beta-blocker, endothelial dysfunction,  
meta-analysis, arterial hypertension
Introduction
Endothelium is the innermost layer of blood 
vessels responsible for regulation of blood flow, 
inflammation response and hemostasis. Endothelial 
dysfunction (ED) frequently precedes cardiovas-
cular diseases (CVD) and is a well-established 
risk factor of major adverse cardiac events [1]. 
Nowadays, one can assess endothelial function 
using invasive or non-invasive procedures. One of 
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the most popular methods of endothelial function 
assessment is still flow-mediated dilatation (FMD). 
In this method, the brachial artery diameter is 
measured before and after endothelial-dependent 
vasodilatation provoked by temporary ischemia.
Beta-blockers were introduced to the therapy 
in the 1960s. Their effectiveness in the therapy of 
hypertension, coronary heart disease and heart 
failure is well documented [2, 3]. Of the two types 
of beta-adrenergic receptors, one (beta1) is mainly 
found in the heart. The effects of beta1-receptor 
stimulation include change of chronotropy (in-
creased heart rate), inotropy (increased force of 
heart contraction), lusitropy (increased myocardial 
relaxation) and dromotropy (increased conduction 
speed). Modulation of any of these attributes by 
beta-blockers can be a goal of a CVD therapy.
Three generations of beta-blockers are avail-
able: non-selective, selective and beta-blockers 
with additional vasodilation properties. Among the 
3rd generation beta-blockers, are those with a nitric 
oxide-dependent vasodilatory activity, which can be 
crucial for endothelial function improvement [4].
The reversible character of ED is well known 
[5]. In this paper, we attempted to assess the ef-
fectiveness of beta-blockers in improving endothe-
lial function. Additionally, a comparison between 
particular generations of beta-blockers and other 
popular groups of cardiovascular treatment agents 
was performed according to their effects on en-
dothelial function based on published randomized 
controlled trials.
Materials and methods
Study selection
Two co-authors independently searched the 
PubMed Database and the Cochrane Central 
Register of Controlled Trials (CENTRAL) for 
randomized controlled trials published before 
March 2014. To find suitable studies we used the 
following search formula: [(endothelial function) 
OR (flow mediated dilation)] AND [(beta-blockers) 
OR (beta andrenolytics) OR acebutolol OR ateno-
lol OR betaxolol OR bisoprolol OR carvedilol OR 
labetalol OR metoprolol OR nadolol OR nebivolol 
OR pindolol OR propranolol OR sotalol)]. After 
selection of full text articles, selected references 
in particular studies were also analyzed.
Inclusion criteria
We included only studies/reports fulfilling 
simultaneously all of the following criteria: 
1) randomized, 2) controlled with placebo or other 
active treatment agents, 3) parallel or cross-over 
trials with 4) double or single blinding or end-
point blinding; 5) in at least one of the arms of the 
study, beta-blocker administration had to be newly 
started; 6) ultrasound FMD measures were per-
formed at least twice: before and after treatment; 
7) diagnosis of CVD and/or diabetes mellitus in 
the study group was essential for trial inclusion; 
8) published in English between January 1992 and 
March 2014. Characteristics of the trials included 
in the present meta-analysis are shown in Table 1. 
The quality of the trials was assessed by the 
Effective Public Health Practice Project Quality 
Assessment Tool [6]. Quality of the majority of the 
studies was assessed as strong.
Data extraction
Titles, abstracts and full texts indicated by the 
search engines used were independently reviewed 
by two co-authors. After selection of full texts, 
consensus between these reviewers was necessary 
for study inclusion. In case of any discrepancies, 
decision of a third reviewer was binding. For each 
study, we collected the following information: first 
author, number of patients in each arm of the study, 
their age and sex distribution, diagnosed diseases, 
treatment agents with doses, time of follow-up and 
FMD values before and after treatment. In case 
of two or more FMD measurements during the 
treatment period, the last one was considered. To 
obtain missing data, e-mails to corresponding au-
thors were sent. When no information about exact 
mean FMD values was provided, we performed an 
evaluation based on figures or graphs.
Statistical analysis
The meta-analysis was performed based on 
generic inverse variance according to each study. 
For each study, mean changes of FMD values and 
standard deviations were calculated. To calculate 
standard deviation within repeated measurements, 
we based on the difference between mean values of 
FMD and the p-value for a paired t-test. P-values 
were converted to t-values using SAS 9.2. software. 
When no exact p-values could be obtained, bounded 
values were assumed. For non-statistically signifi-
cant differences between baseline and final FMD 
measurements, the correlation coefficient between 
the measurements was presumed to be 0.5. When 
an interquartile range was reported, we converted 
it to standard deviation based on Cochrane recom-
mendations [7]. For studies with more than one 
arm with the same group of drugs, we combined 
groups and assumed a single pair-wise comparison. 
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Heterogeneity (I2) between studies was assessed 
with c2 test for heterogeneity [7]. For heterogene-
ity level > 50% random-effects model was used, 
otherwise, fixed-effects model was presumed. Sta-
tistical significance of pooled treatment effect was 
considered for p-values < 0.05. The general part 
of the meta-analysis was calculated using Review 
Manager 5.2 (The Cochrane Collaboration).
Results
Criteria for study inclusion
Based on the search formula, we found 1,741 
studies in the PubMed Database and 91 studies 
in the Cochrane Database. Altogether, the two 
co-authors selected independently overall 27 full-
text studies for further analysis. After a careful 
assessment of the trials, 11 were excluded from 
the meta-analysis: 5 without placebo or other-drug 
control group, 1 without randomization, 1 with open 
label design, 2 with combined pharmacotherapy, 
1 with endothelial function assessed using Periph-
eral Arterial Tonometry and 1 with FMD values 
adjusted for brachial artery diameter. A total of 
1,273 patients from 16 studies were finally in-
cluded into the meta-analysis. Their mean ages in 
those groups ranged from 44.9 to 63.2 years. The 
follow-up duration varied from 1 to 12 months, with 
13 of the 16 studies (81.3%) focused on patients with 
diagnosed hypertension. The flowchart in Figure 1 
illustrates the consecutive steps of study selection.
FMD measurements
The duration of ischemia and cuff position 
during FMD measurement was reported in 15 of 
the 16 studies (except for Koh et al. [8]). In 
14 out of 15 studies, the ischemia lasted for 5 min, 
in 1 study it was 4.5 min [9]. In 12 studies, the 
cuff was placed on the forearm and in 3 studies 
measurements was performed with cuff placed on 
the arm [10–12]. Six studies reported the number 
of observers who assessed FMD [9, 10, 13–16]. In 
5 of those studies, only 1 person was responsible 
for the FMD measurements. The FMD values 
before and after treatment and their changes are 
gathered in Table 2.
Beta-blockers vs. placebo
Four out of 16 studies compared the FMD 
change between the beta-blockers and placebo 
groups comprising a total of 360 patients [8, 9, 
13, 17]. Period between baseline and final FMD 
measurements ranged from 1 to 12 months. The 
2 subgroups of patients analyzed by Lin et al. [9]: 
the one with coronary artery disease and hyperten-
sion and the other with hypertension alone, were 
combined into one group.
The main conclusion for this analysis is that 
there was a statistically significant effect of beta-
blockers treatment on the endothelial function 
compared to placebo, with mean difference (MD) 
of 0.83; 95% confidence interval (CI) 0.11–1.55; 
p = 0.02. The heterogeneity of those studies was 
Figure 1. Consecutive steps of study selection.
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assessed as non important, I2 = 40%; p = 0.17. 
A forest plot illustrating the comparison between 
beta-blockers and placebo is presented in Figure 2A.
Third vs. second generation of beta-blockers
Seven of 16 studies, comprising a total of 366 
patients compared the effect of 3rd vs 2nd generation 
beta-blockers on FMD change [10–12, 15, 18–20]. 
Period between baseline and final FMD measure-
ments ranged from 1 month to 48 weeks. The 3rd gen-
eration beta-blockers investigated were: carvedilol 
and nebivolol, and the 2nd  generation ones: atenolol 
and metoprolol. The 3rd generation beta-blockers 
gave a significantly better improvement of FMD 
compared with 2nd  generation beta-blockers, with 
a MD of 1.65; 95% CI 0.17–3.11; p = 0.03. 
The heterogeneity of the analyzed trials was as-
sessed as substantial to considerable, I2 = 90%, 
p < 0.0001. A forest plot illustrating the compari-
son between 3rd and 2nd generation of beta-blockers 
is shown in Figure 2B. In addition to a 3rd and 
2nd generation comparison, Zepeda et al. [14] 
also compared with each other the effects of two 
3rd generation beta-blockers: carvedilol and nebivolol. 
The two agents gave a similar improvement of FMD, 
with a MD of: 3.75 ± 8.67 for carvedilol and 4.7 ± 
Figure 2. Forest plot presenting effect of (A) beta-blockers and placebo; B. Second and third generation beta-blockers; 
C. Beta-blockers and angiotensin converting enzyme inhibitors (ACEI); D. Beta-blockers and angiotensin receptor 
blockers (ARB); E. Beta-blockers and calcium channel blockers (CCB) on flow mediated dilation changes.
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± 12.1 for nebivolol (p > 0.05). Similarly, there was 
no difference between the 2nd generation beta-block-
ers: atenolol and metoprolol in the study of Heffer-
nan et al. [21], the mean FMD changes were: 0.70 ± 
± 0.89 and 1.90 ± 0.89, respectively (p > 0.05).
Beta-blockers vs. other antihypertensive drugs
Five of the 16 studies analyzed effects of 
different classes of antihypertensive drugs on 
endothelial function [8, 12, 16, 22, 23]. Three 
of them involving 191 patients compared the 
effect of angiotensin converting enzyme inhibi-
tors (ACEI) and beta-blockers on FMD changes 
[7, 12, 23]. Period between baseline and final 
FMD measurements varied from 8 weeks to 
6 months. The efficacy of beta-blockers was signifi-
cantly lower compared with ACEI, with the MD of 
–0.79; 95% CI –1.37–(–0.21); p = 0.008 (Fig. 2C). 
A similar difference was observed when only 
3rd generation beta-blockers were compared with 
ACEI, giving the MD of: –0.97; 95% CI –1.60–
(–0.35); p = 0.002. Four studies including 242 
patients with period between FMD measurements 
ranging from 1 to 6 months compared beta-blockers 
and angiotensin receptor blockers (ARB) [8, 12, 
16, 23]. The two groups of drugs produced simi-
lar FMD changes, with the MD of –0.31; 95% CI 
–1.18–(–0.55); p = 0.48 (Fig. 2D). The effects of 
beta-blockers and calcium channel blockers (CCB) 
on endothelial function were analyzed in two stud-
ies including 174 patients with the period between 
FMD measurements of 8 weeks and 6 months, 
respectively [7, 12]. There were no statistically 
significant differences between the two groups 
of drugs, the MD being 0.58; 95% CI –1.14–2.30; 
p = 0.51 (Fig. 2E). Koh et al. [8] compared the ef-
fects of beta-blockers and diuretic therapy on FMD 
change. Beta-blockers and hydrochlorothiazide had 
similar effects on FMD change: 0.8 ± 2.04 and 0.71 
± 1.94, respectively (p > 0.05).
Beta-blockers vs. ivabradine
Nerla et al. [13] compared the effect of at-
enolol and ivabradine on endothelial function in 
41 patients with diabetes mellitus type 2. After 
4 weeks of treatment, the change in the FMD value 
was significantly higher in the atenolol group than 
in the ivabradine group: 1.6 ± 3.61 vs. –0.3 ± 1.66; 
p = 0.02.
Discussion
To the best of our knowledge, this is the first 
meta-analysis of the effects of beta-blockers on 
endothelial function as assessed by FMD. The main 
finding of this study is that beta-blockers signifi-
cantly improve the endothelial function compared 
with placebo. Moreover, the FMD improvement is 
significantly higher for 3rd generation beta-blockers 
compared to the 2nd generation ones. Compared to 
other antihypertensive drugs, beta-blockers show 
similar effect on endothelial function as ARB, CCB 
or diuretics. However, beta-blockers are less effec-
tive than ACEI.
The effects of beta-blockers on endothelial 
function seem to be indirect. There is no strong 
evidence of an interaction between beta-blockers 
or their metabolites with endothelial cells. Earlier 
studies have amply described an impaired endothe-
lial-dependent response of arteries in hypertensive 
subjects [24]. The pathomechanism of endothelial 
dysfunction as a response to high blood pressure is 
intricate. First, higher blood pressure favors reduc-
tion of nitric oxide (NO) level, which is predominant-
ly responsible for decreased endothelium-dependent 
vasodilatation. Persistently decreased shear stress 
leads to reduction of endothelial nitric oxide syn-
thase (eNOS) level in hypertensive patients [25]. 
Moreover, hypertension predisposes to higher 
serum levels of eNOS inhibitors (e.g. asymmetric 
dimethylarginine) and therefore, additionally results 
in decreased local NO levels. Second, an increased 
oxidative stress, due to higher blood pressure is 
a factor strongly impairing endothelial function [25, 
26]. Finally, the damage of endothelial cells caused 
by high blood pressure is tightly connected with an 
increased local inflammatory response resulting in 
remodeling of vessel walls leading to their impaired 
relaxation [25].
Among the four studies comparing beta-block-
ers with placebo included in our meta-analysis, 
only Matsuda et al. [17] studied the effect of 
3rd generation beta-blocker (carvedilol). In that study, 
the improvement of FMD values was the strongest. 
Carvedilol is a non-selective agent blocking not 
only beta-adrenergic but also alpha1-adrenergic 
receptors. Alfa-adrenergic blocking plays a sub-
stantial beneficial role in endothelial function 
improvement [27]. Moreover, the exceptional an-
tioxidant properties of carvedilol may additionally 
enhance the favorable effect of alpha1-adrenergic 
receptors blockade on endothelial function [28].
Interestingly, in 2 of the 4 placebo-controlled 
studies analyzed here, the FMD values remarkably 
increased also in the placebo groups [8, 9]. This 
situation suggests influence of other factors (e.g., 
better medical care) on endothelial function despite 
a lack of hypertension treatment and implies that 
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trials with no-treatment group give unrealistically 
positive outcomes.
An advantage of 3rd generation beta-blockers 
compared with 2nd generation ones has been shown 
in this meta-analysis. The beneficial effects of 
carvedilol on endothelial function improvement 
are discussed above.
Similarly to beta-blockers, the effect of other 
antihypertensive drugs on endothelial function 
seems to be strictly connected with blood pressure 
reduction. Additionally, the antioxidative properties 
of ACEI, ARB and CCB are well proven [29–31]. 
Earlier studies have suggested that the contribu-
tion of these agents to oxidative stress reduction is 
one of the main mechanisms of endothelial function 
improvement. Some investigators have suggested 
an important role of antihypertensive drugs in the 
reduction of inflammation response. However, Koh 
et al. [8] showed that none of those agents could 
reduce the C-reactive protein level reduction after 
8 weeks of treatment. Noticeably, Nishizaka et al. 
[32] showed that endothelial function measured 
with FMD is negatively correlated with serum 
aldosterone level. The complex effects of ACEI 
on the renin–angiotensin–aldosterone system can 
explain the advantage of ACEI over beta-blockers 
in endothelial function improvement [33].
Limitations of the study
One of the main limitations of the present 
meta-analysis is indiscriminate inclusion of stud-
ies using both 2nd and 3rd generation beta-blockers. 
Selection of a single generation of beta-blockers 
could provide more homogenous subgroups, how-
ever, differences within these subgroups can also 
be significant. Moreover, to increase the number of 
participants we decided not to limit the analysis to 
patients with a diagnosed hypertension, in whom 
the effect of beta-blockers on endothelial function 
is well studied. The differences between treatment 
periods in individual studies additionally increased 
the heterogeneity of data. The strict inclusion 
criteria according to study the design reduced the 
number of analyzed trials, but on the other hand 
contributed to bias reduction. Finally, the lack of 
exact p-values for FMD changes in some studies 
increased standard error for the differences and 
reduced the effect of those studies on the meta-
analysis results.
Conclusions
The meta-analysis presented here indicates 
that beta-blockers improve the endothelial function 
compared with placebo. Moreover, 3rd generation 
beta-blockers are significantly better than 2nd gen-
eration ones in improving FMD. Beta-blockers 
have a similar effect on endothelial function as 
ARB, CCB or diuretics, but are inferior in this 
respect to ACEI.
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